Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial

Fig. 3

Consistent treatment effect of empagliflozin vs. placebo in those with and without metabolic syndrome at baseline. *Excluding fatal stroke. Cox models include terms for baseline age, sex, HbA1c, eGFR, geographical region, treatment, MetS at baseline and treatment*MetS at baseline interaction. p-values for treatment-by-subgroup interaction were obtained from tests of homogeneity of treatment group differences among subgroups with no adjustment for multiple testing. CV cardiovascular, HHF hospitalization for heart failure, MetS metabolic syndrome, py patient-years

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840